Mehmet Sarihan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mehmet Sarihan has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Murat Kasap
Department of Medical Biology, Faculty of Medicine, Kocaeli University, Kocaeli, Turkiye
12 shared publications - Gurler Akpinar
Department of Medical Biology, Faculty of Medicine, Kocaeli University, Kocaeli, Turkiye
10 shared publications - Elifcan Kocyigit
Department of Medical Biology Protein Research and Proteomics Laboratory, Faculty of Medicine, Kocaeli University, Umuttepe, Izmit, Türkiye
3 shared publications - Banu Iskender
Department of Medical Biology Protein Research and Proteomics Laboratory, Faculty of Medicine, Kocaeli University, Umuttepe, Izmit, Türkiye
2 shared publications - Sevinc Yanar
Department of Medical Biology, Faculty of Medicine, Ankara Yildirim Beyazit University, Ankara, Türkiye
2 shared publications - Asuman Deveci Ozkan
Department of Medical Biology, Faculty of Medicine, Sakarya University, 54290 Sakarya, Türkiye
1 shared publication
Latest Publications
- Open Access
Time-Resolved Proteomics of a Polyglutamine-Expanded Huntingtin in vitro Cell Model Reveals Early RNA-Regulatory Compensation and Late Respiratory-Chain Remodeling
Huntington’s disease (HD) is caused by a polyglutamine-expanded huntingtin protein that exerts progressive cellular toxicity. However, the temporal order of pathogenic events, and in particular which changes arise early and which emerge late, remains incompletely defined, despite their distinct therapeutic implications. To examine this trajectory, we profiled the proteome of a huntingtin-expressing cell model at early (72 h) and late (144 h) stages. Rather than a linear progression, the proteome changed in two distinct stages. At the early stage, cells showed increased abundance of RNA-processing, splicing, and protein-synthesis proteins, which may reflect an adaptive response to preserve gene-expression fidelity under stress. By the late stage, many of these proteins were depleted and mitochondrial energy-metabolism proteins dominated the response. Notably, 85% of proteins altered at both time points reversed direction between stages (95% at a false-discovery rate below 5%), and all reversals were supported by a significant genotype-by-time interaction, indicating that mutant huntingtin reorganizes the proteome rather than amplifying a fixed set of perturbations. Subunit-level analysis of the respiratory chain showed that Complex IV and ATP synthase subunits were reduced at 72 h, whereas at 144 h subunits of all five complexes were broadly increased, most strongly in Complex I and III, with a few distal subunits (COX5B, ATP5F1A, ATP5F1B) remaining reduced. Leveraging this proteomic map, we applied an AI-assisted, direction-aware drug repurposing strategy. Of 1,712 differentially abundant proteins, 498 were druggable, 109 had at least one agent whose mechanism was concordant with the required correction, and 89 of these 109 proteins mapped to at least one agent listed as approved in the source databases (56 to an agent with current regulatory approval). These included the approved Complex I inhibitor metformin, the investigational Complex I inhibitor ME-344, and pathway-level mitochondria-directed agents (elamipretide/SS-31, approved only for Barth syndrome; MitoQ, a dietary supplement), several of which have previously been evaluated in HD models. Collectively, these findings describe a two-stage proteomic response to mutant huntingtin in this cell model and suggest a putative early window for preclinical intervention testing, before late respiratory-chain remodeling is established.
Open AccessTime-Resolved Proteomics of a Polyglutamine-Expanded Huntingtin in vitro Cell Model Reveals Early RNA-Regulatory Compensation and Late Respiratory-Chain Remodeling
Huntington’s disease (HD) is caused by a polyglutamine-expanded huntingtin protein that exerts progressive cellular toxicity. However, the temporal order of pathogenic events, and in particular which changes arise early and which emerge late, remains incompletely defined, despite their distinct therapeutic implications. To examine this trajectory, we profiled the proteome of a huntingtin-expressing cell model at early (72 h) and late (144 h) stages. Rather than a linear progression, the proteome changed in two distinct stages. At the early stage, cells showed increased abundance of RNA-processing, splicing, and protein-synthesis proteins, which may reflect an adaptive response to preserve gene-expression fidelity under stress. By the late stage, many of these proteins were depleted and mitochondrial energy-metabolism proteins dominated the response. Notably, 85% of proteins altered at both time points reversed direction between stages (95% at a false-discovery rate below 5%), and all reversals were supported by a significant genotype-by-time interaction, indicating that mutant huntingtin reorganizes the proteome rather than amplifying a fixed set of perturbations. Subunit-level analysis of the respiratory chain showed that Complex IV and ATP synthase subunits were reduced at 72 h, whereas at 144 h subunits of all five complexes were broadly increased, most strongly in Complex I and III, with a few distal subunits (COX5B, ATP5F1A, ATP5F1B) remaining reduced. Leveraging this proteomic map, we applied an AI-assisted, direction-aware drug repurposing strategy. Of 1,712 differentially abundant proteins, 498 were druggable, 109 had at least one agent whose mechanism was concordant with the required correction, and 89 of these 109 proteins mapped to at least one agent listed as approved in the source databases (56 to an agent with current regulatory approval). These included the approved Complex I inhibitor metformin, the investigational Complex I inhibitor ME-344, and pathway-level mitochondria-directed agents (elamipretide/SS-31, approved only for Barth syndrome; MitoQ, a dietary supplement), several of which have previously been evaluated in HD models. Collectively, these findings describe a two-stage proteomic response to mutant huntingtin in this cell model and suggest a putative early window for preclinical intervention testing, before late respiratory-chain remodeling is established.
- Open Access
- 27 February 2026
- Published by Kocaeli University in Acta Medica Nicomedia
- Vol. 9, 1-8
Database Selection Shapes Protein Identification and Quantification in Proteomics
Objective: This study evaluates the effect of protein database composition, size, and subcellular specificity on protein identification, peptide coverage, and quantitative accuracy in MS-based proteomic analyses. Methods: Whole proteome analyses were performed using HeLa cells. Label-free quantification (LFQ) analyses of secretome samples were conducted using the breast cell lines MCF-10A and MDA-MB-231 to assess database-related effects on quantification. Nuclear proteome analyses were carried out using raw MS data generated in previous studies. Reviewed, unreviewed, and subcellular proteome–specific databases were systematically analyzed and compared to evaluate the effect of database on LC-MS/MS results. Results: Using unreviewed protein entries did not result in a meaningful increase in protein or peptide identifications. Results showed that using gene name provided more accurate results comparing with accession number. In addition, subcellular proteome–specific databases improved peptide-to-protein assignment consistency and reduced ambiguity. Even modest differences in peptide counts propagated into downstream quantitative analyses, affecting abundance ratios. Conclusion: Results indicate that database choice plays a crucial role in proteomic data clarity, consistency, and quantitative reliability, and that the use of curated, reviewed, and target-specific subcellular databases enhances analytical confidence, emphasizing the importance of careful database selection in MS-based proteomic studies.
- 27 February 2026
- Published by Kocaeli University in Acta Medica Nicomedia
- Vol. 9, 1-8
Open AccessDatabase Selection Shapes Protein Identification and Quantification in Proteomics
Objective: This study evaluates the effect of protein database composition, size, and subcellular specificity on protein identification, peptide coverage, and quantitative accuracy in MS-based proteomic analyses. Methods: Whole proteome analyses were performed using HeLa cells. Label-free quantification (LFQ) analyses of secretome samples were conducted using the breast cell lines MCF-10A and MDA-MB-231 to assess database-related effects on quantification. Nuclear proteome analyses were carried out using raw MS data generated in previous studies. Reviewed, unreviewed, and subcellular proteome–specific databases were systematically analyzed and compared to evaluate the effect of database on LC-MS/MS results. Results: Using unreviewed protein entries did not result in a meaningful increase in protein or peptide identifications. Results showed that using gene name provided more accurate results comparing with accession number. In addition, subcellular proteome–specific databases improved peptide-to-protein assignment consistency and reduced ambiguity. Even modest differences in peptide counts propagated into downstream quantitative analyses, affecting abundance ratios. Conclusion: Results indicate that database choice plays a crucial role in proteomic data clarity, consistency, and quantitative reliability, and that the use of curated, reviewed, and target-specific subcellular databases enhances analytical confidence, emphasizing the importance of careful database selection in MS-based proteomic studies.
- Open Access
- 6 February 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Conjoining cell reprogramming and mass spectrometry to identify the proteomic variations in the reprogrammed bladder cancer cells: finding cues of normalisation
Background: Cancer cell reprogramming is a critical area of research that holds the power to transform malignancies into benign states while revealing key mechanisms of carcinogenesis. This study aimed to develop a more effective in vitro bladder cancer model using induced pluripotent stem cell technology and identify potential diagnostic and therapeutic biomarkers for bladder cancer. Methods: Sendai virus-based reprogramming was utilised to reprogram the bladder cancer cell line HTB-5. The reprogrammed cells were characterised by expressing pluripotency-associated markers, colony formation abilities, cell migration, and drug responses. LC-MS/MS reveals changes in protein composition among parental cancer cells, reprogrammed cancer cells, and normal uroepithelial cells. Results: Reprogrammed bladder cancer cells display the expression of pluripotency-associated markers and demonstrate altered behaviours, including cell migration and responses to anticancer therapies. The genome-wide regulation by Sendai-virus delivery of Yamanaka factors resulted in distinctive protein expression patterns in reprogrammed bladder cancer cells, indicative of the pluripotency as well as spontaneous differentiation. A total of 297 dysregulated proteins in bladder cancer cells were normalised upon reprogramming. We proposed 25 potential biomarker candidates for diagnostic and therapeutic purposes, of which 12 candidates were demonstrated for the first time at the protein level. Conclusions: Differentially regulated proteins in parental bladder cancer cells and reprogrammed bladder cancer cells highlighted the critical protein-protein interactions that indicate the normalisation process of the parental bladder cancer cells. These cues could be used to pinpoint the candidate proteins to optimise the controlled partial/full reprogramming, to discover the therapeutic potential of reprogramming and to propose clinically relevant biomarker candidates.
- 6 February 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Open AccessConjoining cell reprogramming and mass spectrometry to identify the proteomic variations in the reprogrammed bladder cancer cells: finding cues of normalisation
Background: Cancer cell reprogramming is a critical area of research that holds the power to transform malignancies into benign states while revealing key mechanisms of carcinogenesis. This study aimed to develop a more effective in vitro bladder cancer model using induced pluripotent stem cell technology and identify potential diagnostic and therapeutic biomarkers for bladder cancer. Methods: Sendai virus-based reprogramming was utilised to reprogram the bladder cancer cell line HTB-5. The reprogrammed cells were characterised by expressing pluripotency-associated markers, colony formation abilities, cell migration, and drug responses. LC-MS/MS reveals changes in protein composition among parental cancer cells, reprogrammed cancer cells, and normal uroepithelial cells. Results: Reprogrammed bladder cancer cells display the expression of pluripotency-associated markers and demonstrate altered behaviours, including cell migration and responses to anticancer therapies. The genome-wide regulation by Sendai-virus delivery of Yamanaka factors resulted in distinctive protein expression patterns in reprogrammed bladder cancer cells, indicative of the pluripotency as well as spontaneous differentiation. A total of 297 dysregulated proteins in bladder cancer cells were normalised upon reprogramming. We proposed 25 potential biomarker candidates for diagnostic and therapeutic purposes, of which 12 candidates were demonstrated for the first time at the protein level. Conclusions: Differentially regulated proteins in parental bladder cancer cells and reprogrammed bladder cancer cells highlighted the critical protein-protein interactions that indicate the normalisation process of the parental bladder cancer cells. These cues could be used to pinpoint the candidate proteins to optimise the controlled partial/full reprogramming, to discover the therapeutic potential of reprogramming and to propose clinically relevant biomarker candidates.
- 14 January 2026
- Published by Balikesir Universitesi Fen Bilimleri Enstitusu Dergisi in Balıkesir Üniversitesi Fen Bilimleri Enstitüsü Dergisi
- Vol. 28 (1) , 449-465
Endoplasmic reticulum-localized TurboID-mediated labelling reveals distinct secretome profiles of MCF-10A and MDA-MB-231 cells
Breast cancer is one of the most prevalent cancers and the leading causes of cancer-related deaths. The lack of reliable biomarkers for accurate subtyping and early diagnosis continues to hinder early detection and treatment. Secretome proteins represent an accessible and valuable source of biomarkers due to their roles in cell communication, signalling and shaping the extracellular microenvironment. In this study, secretome proteins from two cell lines, MCF-10A and MDA-MB-231, representing healthy and aggressive breast cells, respectively, were labelled with ER-localized TurboID-mediated enzymatic biotinylation approach at the endoplasmic reticulum. The biotinylated samples were enriched using streptavidin-coated magnetic beads and analysed by label-free quantitation using nHPLC LC-MS/MS. The regulated proteins were subjected to bioinformatics analyses using STRING and g:Profiler tools to identify candidate biomarkers. Proteomic analysis identified 206 proteins, with approximately 82% belonged to secretome proteins. Among them, 65 were differentially regulated which were associated with hydrolytic activity, cell adhesion, and lipid metabolism. CST1, APOC1, and POSTN had previously been associated with cancer, while TEX10, LZIC, and PSMA3 were implicated in breast cancer for the first time. Our findings demonstrates extensive secretome remodelling in invasive breast cancer cells, unveiling potential secreted biomarker candidates that may improve breast cancer diagnosis and treatment strategies.
- 14 January 2026
- Published by Balikesir Universitesi Fen Bilimleri Enstitusu Dergisi in Balıkesir Üniversitesi Fen Bilimleri Enstitüsü Dergisi
- Vol. 28 (1) , 449-465
Endoplasmic reticulum-localized TurboID-mediated labelling reveals distinct secretome profiles of MCF-10A and MDA-MB-231 cells
Breast cancer is one of the most prevalent cancers and the leading causes of cancer-related deaths. The lack of reliable biomarkers for accurate subtyping and early diagnosis continues to hinder early detection and treatment. Secretome proteins represent an accessible and valuable source of biomarkers due to their roles in cell communication, signalling and shaping the extracellular microenvironment. In this study, secretome proteins from two cell lines, MCF-10A and MDA-MB-231, representing healthy and aggressive breast cells, respectively, were labelled with ER-localized TurboID-mediated enzymatic biotinylation approach at the endoplasmic reticulum. The biotinylated samples were enriched using streptavidin-coated magnetic beads and analysed by label-free quantitation using nHPLC LC-MS/MS. The regulated proteins were subjected to bioinformatics analyses using STRING and g:Profiler tools to identify candidate biomarkers. Proteomic analysis identified 206 proteins, with approximately 82% belonged to secretome proteins. Among them, 65 were differentially regulated which were associated with hydrolytic activity, cell adhesion, and lipid metabolism. CST1, APOC1, and POSTN had previously been associated with cancer, while TEX10, LZIC, and PSMA3 were implicated in breast cancer for the first time. Our findings demonstrates extensive secretome remodelling in invasive breast cancer cells, unveiling potential secreted biomarker candidates that may improve breast cancer diagnosis and treatment strategies.
- Open Access
- 28 October 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF BIOLOGY
- Vol. 49 (6) , 700-711
Evaluating SH-SY5Y cells as a dopaminergic neuronal model: morphological, transcriptomic, and proteomic insights
Background/aim: The SH-SY5Y neuroblastoma cell line is a popular in vitro model for neurodegenerative disease research, especially Parkinson’s disease (PD) research, but its use is complicated by limitations like the persistence of neuroblastoma-like features, unstable differentiation, mitochondrial dysfunction, and cellular stress. To address these limitations, this study tested a blended, nine-day differentiation protocol that sequentially applied all-trans retinoic acid (RA), brain-derived neurotrophic factor (BDNF), and dibutyryl cyclic adenosine monophosphate (dbcAMP). By evaluating key neuronal, dopaminergic, and PD-related markers, the research aims to determine if these differentiated SH-SY5Y cells are a suitable model for studying PD. Materials and methods: A blended differentiation protocol using RA, BDNF, and dbcAMP was applied to SH-SY5Y cells. Morphological changes were evaluated by immunofluorescence microscopy. Furthermore, mostly dopaminergic neuronal markers associated with PD were used for characterization purposes. Nanoliquid chromatography coupled with tandem mass spectrometry proteome analysis was performed to identify changes in protein expression related to differentiation. Results: Differentiation led to neuron-like morphology with extended neurites. Gene expression analyses revealed upregulation of several neuronal markers, such as Nestin and MAP2, indicating progression from progenitor to neuron-like states. Furthermore, some dopaminergic markers, such as TH and Nurr1, showed elevated expression with asynchronous expression patterns, suggesting heterogeneity in the differentiation process. Proteomic analysis indicated significant changes in cell differentiation and neurogenesis. Transient expression of key neuronal markers was observed. The cells required continuous external stimuli. Conclusion: While SH-SY5Y cells exhibited dopaminergic characteristics following the blended differentiation protocol, the transient expression of key neuronal markers and the need for continuous external stimuli raised concerns about the stability and functional maturity of these differentiated cells as an in vitro PD model. These findings suggest that SH-SY5Y cells might not fully capture the properties of mature neurons.
- 28 October 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF BIOLOGY
- Vol. 49 (6) , 700-711
Open AccessEvaluating SH-SY5Y cells as a dopaminergic neuronal model: morphological, transcriptomic, and proteomic insights
Background/aim: The SH-SY5Y neuroblastoma cell line is a popular in vitro model for neurodegenerative disease research, especially Parkinson’s disease (PD) research, but its use is complicated by limitations like the persistence of neuroblastoma-like features, unstable differentiation, mitochondrial dysfunction, and cellular stress. To address these limitations, this study tested a blended, nine-day differentiation protocol that sequentially applied all-trans retinoic acid (RA), brain-derived neurotrophic factor (BDNF), and dibutyryl cyclic adenosine monophosphate (dbcAMP). By evaluating key neuronal, dopaminergic, and PD-related markers, the research aims to determine if these differentiated SH-SY5Y cells are a suitable model for studying PD. Materials and methods: A blended differentiation protocol using RA, BDNF, and dbcAMP was applied to SH-SY5Y cells. Morphological changes were evaluated by immunofluorescence microscopy. Furthermore, mostly dopaminergic neuronal markers associated with PD were used for characterization purposes. Nanoliquid chromatography coupled with tandem mass spectrometry proteome analysis was performed to identify changes in protein expression related to differentiation. Results: Differentiation led to neuron-like morphology with extended neurites. Gene expression analyses revealed upregulation of several neuronal markers, such as Nestin and MAP2, indicating progression from progenitor to neuron-like states. Furthermore, some dopaminergic markers, such as TH and Nurr1, showed elevated expression with asynchronous expression patterns, suggesting heterogeneity in the differentiation process. Proteomic analysis indicated significant changes in cell differentiation and neurogenesis. Transient expression of key neuronal markers was observed. The cells required continuous external stimuli. Conclusion: While SH-SY5Y cells exhibited dopaminergic characteristics following the blended differentiation protocol, the transient expression of key neuronal markers and the need for continuous external stimuli raised concerns about the stability and functional maturity of these differentiated cells as an in vitro PD model. These findings suggest that SH-SY5Y cells might not fully capture the properties of mature neurons.
- Open Access
- 25 April 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF BIOLOGY
- Vol. 49 (2) , 162-174
A tetracycline-inducible Split TurboID system for specific biotinylation and identification of nuclear proteins from HEK293T cells
Background/aim: To overcome the limitations of conventional organelle isolation methods including low purity, low yield, sample degradation, scalability and the need for multiple centrifugation steps, an improved nuclear protein enrichment approach was developed using the modified Split TurboID biotin ligase enzyme. Materials and methods: A construct was created in which the N-terminal domain of TurboID, fused to the FK506-binding protein (FKBP) was targeted to the nucleus. This construct was incorporated into a tetracycline-inducible gene expression vector. Similarly, the C-terminal domain of TurboID was fused to the rapamycin-binding domain of mTOR (FRB) and directed to the nucleus. This construct was introduced into a constitutive expression vector. A HEK-293T-TetR+ cell line, stably expressing both fusion proteins, was created. Activation of the N-terminal domain was achieved by tetracycline induction while an active Split-TurboID was formed within the nucleus only after the introduction of rapamycin into the culture medium which facilitated the formation of the FKBP-Rapamycin-FRB complex. Results: The cells expressed N- and C-termini of Split-TurboID and produced an active biotin ligase enzyme in the nucleus, as demonstrated by Western blot and immunofluorescence microscopy analyses. The active enzyme biotinylated both residential nuclear proteins and the proteins that transiently interact with the nucleus. Enrichment and identification of the biotinylated proteins showed that 1518 proteins were identified, of which 78.4% were localized to or colocalized with the nucleus. Comparison with unenrichedsamples confirmed higher confidence in identification of resident nuclear proteins. Cross-referencing with the Human Protein Atlas highlighted the limitations of current databases, 820 proteins match known nuclear proteins and 698 have not been previously annotated. Conclusion: Split-TurboID-based approach effectively minimized background noise arising from nonspecific labeling or imperfect localization and provided an appreciable level of specificity resulting identification of both residential and transiently interacting nuclear proteins.
- 25 April 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF BIOLOGY
- Vol. 49 (2) , 162-174
Open AccessA tetracycline-inducible Split TurboID system for specific biotinylation and identification of nuclear proteins from HEK293T cells
Background/aim: To overcome the limitations of conventional organelle isolation methods including low purity, low yield, sample degradation, scalability and the need for multiple centrifugation steps, an improved nuclear protein enrichment approach was developed using the modified Split TurboID biotin ligase enzyme. Materials and methods: A construct was created in which the N-terminal domain of TurboID, fused to the FK506-binding protein (FKBP) was targeted to the nucleus. This construct was incorporated into a tetracycline-inducible gene expression vector. Similarly, the C-terminal domain of TurboID was fused to the rapamycin-binding domain of mTOR (FRB) and directed to the nucleus. This construct was introduced into a constitutive expression vector. A HEK-293T-TetR+ cell line, stably expressing both fusion proteins, was created. Activation of the N-terminal domain was achieved by tetracycline induction while an active Split-TurboID was formed within the nucleus only after the introduction of rapamycin into the culture medium which facilitated the formation of the FKBP-Rapamycin-FRB complex. Results: The cells expressed N- and C-termini of Split-TurboID and produced an active biotin ligase enzyme in the nucleus, as demonstrated by Western blot and immunofluorescence microscopy analyses. The active enzyme biotinylated both residential nuclear proteins and the proteins that transiently interact with the nucleus. Enrichment and identification of the biotinylated proteins showed that 1518 proteins were identified, of which 78.4% were localized to or colocalized with the nucleus. Comparison with unenrichedsamples confirmed higher confidence in identification of resident nuclear proteins. Cross-referencing with the Human Protein Atlas highlighted the limitations of current databases, 820 proteins match known nuclear proteins and 698 have not been previously annotated. Conclusion: Split-TurboID-based approach effectively minimized background noise arising from nonspecific labeling or imperfect localization and provided an appreciable level of specificity resulting identification of both residential and transiently interacting nuclear proteins.
- 19 March 2024
- Published by Springer Nature in Journal of Fluorescence
- Vol. 35 (4) , 2121-2133
GFP Transfection Alters Protein Expression Patterns in Prostate Cancer Cells: A Proteomic Study
Purpose Green Fluorescent Protein is widely used as a cellular marker tool, but its potential influence on cells has been questioned. Although the potential off-target effects of GFP on tumor cells have been studied to some extent, the findings at the molecular level are insufficient to explain the effect of GFP expression on the tumorigenic capacity of cancer cells. Here, we aimed to investigate the effect of GFP expression on the tumorigenicity of PC3 prostate cancer cells. Methods Using GFP-expressing and wild-type PC-3 cells, xenograft models were generated in athymic BALB/C mice. To identify differentially expressed proteins, the change in cells proteome was investigated by label-free quantification with nano‐high performance liquid chromatography to tandem mass spectrometry (nHPLC‐MS/MS). Proteins that showed significantly altered expression levels were evaluated using the bioinformatics tools. Results Unlike the wild-type PC-3 cells, GFP-expressing cells failed to develop tumor. Comparative proteome analysis of GFP-expressing cells with WT PC-3 cells revealed a total of 216 differentially regulated proteins, of which 98 were upregulated and 117 were downregulated. Conclusion Upon GFP expression, differential changes in several pathways including the immune system, translational machinery, energy metabolism, elements of cytoskeletal and VEGF signaling pathway were observed. Therefore, care should be taken into account to prevent reporting deceitful mechanisms generated from studies utilizing GFP. Graphical Attenuation of Tumorigenicity of PC-3 Cells after Stably Expressing GFP. Immune response, translational activity, energy metabolism, cytoskeletal components, and VEGF Signaling were regulated in GFP-expressing cells
- 19 March 2024
- Published by Springer Nature in Journal of Fluorescence
- Vol. 35 (4) , 2121-2133
GFP Transfection Alters Protein Expression Patterns in Prostate Cancer Cells: A Proteomic Study
Purpose Green Fluorescent Protein is widely used as a cellular marker tool, but its potential influence on cells has been questioned. Although the potential off-target effects of GFP on tumor cells have been studied to some extent, the findings at the molecular level are insufficient to explain the effect of GFP expression on the tumorigenic capacity of cancer cells. Here, we aimed to investigate the effect of GFP expression on the tumorigenicity of PC3 prostate cancer cells. Methods Using GFP-expressing and wild-type PC-3 cells, xenograft models were generated in athymic BALB/C mice. To identify differentially expressed proteins, the change in cells proteome was investigated by label-free quantification with nano‐high performance liquid chromatography to tandem mass spectrometry (nHPLC‐MS/MS). Proteins that showed significantly altered expression levels were evaluated using the bioinformatics tools. Results Unlike the wild-type PC-3 cells, GFP-expressing cells failed to develop tumor. Comparative proteome analysis of GFP-expressing cells with WT PC-3 cells revealed a total of 216 differentially regulated proteins, of which 98 were upregulated and 117 were downregulated. Conclusion Upon GFP expression, differential changes in several pathways including the immune system, translational machinery, energy metabolism, elements of cytoskeletal and VEGF signaling pathway were observed. Therefore, care should be taken into account to prevent reporting deceitful mechanisms generated from studies utilizing GFP. Graphical Attenuation of Tumorigenicity of PC-3 Cells after Stably Expressing GFP. Immune response, translational activity, energy metabolism, cytoskeletal components, and VEGF Signaling were regulated in GFP-expressing cells
- 29 September 2023
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 262 (1) , 211-221
Is tear proteome profile a predictor of developing uveitis in ANA-positive patients with oligoarticular juvenile idiopathic arthritis?
Purpose Although less than one-third of anti-nuclear antibody (ANA) positive patients with oJIA develop uveitis, ANA positivity is still the most well-known marker for assessing the risk of uveitis in oligoarticular JIA (oJIA). Therefore, novel biomarkers are needed to better assess the risk of developing uveitis. For this purpose, we performed a comparative tear proteome analysis of uveitis patients to reveal the identity of differentially regulated proteins. Design Tear samples were collected using the Schirmer strips in 7 oJIA and 7 oJIA patients with uveitis (oJIA-U). All oJIA-U patients had developed bilateral anterior uveitis and were inactive and topical treatment-free. Methods The nHPLC LC–MS/MS system was used for protein identification and label-free proteome comparisons. The PANTHER and STRING analyses were carried out using UniProt accession numbers of the identified proteins. Results Patient characteristics, e.g., age, gender, disease duration, and treatments were similar. For protein identification, three different databases were searched. Twenty-two, 147, and 258 database searches, respectively. Of these, 15 were common to all three proteome databases. Of these 15 proteins, 10 proteins were upregulated, and 2 were downregulated, based on the twofold regulation criteria. The upregulated proteins were, namely, cystatin-S, secretoglobin family 1D member, opiorphin prepropeptide, mammaglobin-B, lysozyme C, mesothelin, immunoglobulin kappa constant, extracellular glycoprotein lacritin, beta-2-microglobulin, and immunoglobulin J chain. The downregulated proteins were dermcidin and prolactin-inducible protein. Among the differentially regulated proteins, cystatin-S was the most regulated protein with an 18-fold upregulation ratio in tear samples from uveitis patients. Conclusion Here, the identities and regulation ratios of several proteins were revealed when tear samples from uveitis patients were compared to patients without uveitis. These proteins are putative biomarkers for assessing uveitis risk and require further attention.
- 29 September 2023
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 262 (1) , 211-221
Is tear proteome profile a predictor of developing uveitis in ANA-positive patients with oligoarticular juvenile idiopathic arthritis?
Purpose Although less than one-third of anti-nuclear antibody (ANA) positive patients with oJIA develop uveitis, ANA positivity is still the most well-known marker for assessing the risk of uveitis in oligoarticular JIA (oJIA). Therefore, novel biomarkers are needed to better assess the risk of developing uveitis. For this purpose, we performed a comparative tear proteome analysis of uveitis patients to reveal the identity of differentially regulated proteins. Design Tear samples were collected using the Schirmer strips in 7 oJIA and 7 oJIA patients with uveitis (oJIA-U). All oJIA-U patients had developed bilateral anterior uveitis and were inactive and topical treatment-free. Methods The nHPLC LC–MS/MS system was used for protein identification and label-free proteome comparisons. The PANTHER and STRING analyses were carried out using UniProt accession numbers of the identified proteins. Results Patient characteristics, e.g., age, gender, disease duration, and treatments were similar. For protein identification, three different databases were searched. Twenty-two, 147, and 258 database searches, respectively. Of these, 15 were common to all three proteome databases. Of these 15 proteins, 10 proteins were upregulated, and 2 were downregulated, based on the twofold regulation criteria. The upregulated proteins were, namely, cystatin-S, secretoglobin family 1D member, opiorphin prepropeptide, mammaglobin-B, lysozyme C, mesothelin, immunoglobulin kappa constant, extracellular glycoprotein lacritin, beta-2-microglobulin, and immunoglobulin J chain. The downregulated proteins were dermcidin and prolactin-inducible protein. Among the differentially regulated proteins, cystatin-S was the most regulated protein with an 18-fold upregulation ratio in tear samples from uveitis patients. Conclusion Here, the identities and regulation ratios of several proteins were revealed when tear samples from uveitis patients were compared to patients without uveitis. These proteins are putative biomarkers for assessing uveitis risk and require further attention.